{"id":50044,"date":"2022-10-25T16:01:52","date_gmt":"2022-10-25T14:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/"},"modified":"2022-10-25T16:01:52","modified_gmt":"2022-10-25T14:01:52","slug":"hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/","title":{"rendered":"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022"},"content":{"rendered":"
\n

ROCKVILLE, Md. & SHENZHEN, China–(BUSINESS WIRE)–HighTide Therapeutics, Inc. (\u201cHighTide\u201d), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting\u00ae<\/sup> of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 \u2013 8, 2022).\n<\/p>\n

<\/a><\/p>\n

\nA poster presentation titled \u201cEffects of HTD1801 on the Gut Microbiota in Three Rodent Models of Non-alcoholic Fatty Liver Disease and Diabetes\u201d will show how HTD1801 stimulates positive changes in gut microbiota. Emerging evidence supports the bidirectional relationship between intestinal microbiota and liver health. Dysbiosis has been associated with the pathogensis and progression of multiple metabolic diseases and chronic inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). These data showing positive changes in gut microbiota are encouraging and provide another mechanism of action underlying the beneficial effects of HTD1801 in liver and metabolic diseases.\n<\/p>\n

\nAdditionally, a poster presentation titled \u201cGreater Biochemical Improvements With HTD1801 in Patients With PSC and Elevated Baseline Alkaline Phosphatase\u201d will demonstrate how PSC patients treated with HTD1801 exhibited improvement in alkaline phosphatase (ALP). ALP is a key biomarker of cholestasis and liver injury, and serum levels are positively associated with degree of disease severity and risk. The data show that treatment with HTD1801 was associated with overall improvement in markers of cholestasis and liver injury. Importantly, benefit on these liver markers was observed in PSC patients with significantly elevated ALP, a population considered to be at high risk for disease progression.\n<\/p>\n

\nPresentations at the Liver Meeting\u00ae<\/sup> 2022 include:\n<\/p>\n

\nEffects of HTD1801 on the Gut Microbiota in Three Rodent Models of Non-alcoholic Fatty Liver Disease and Diabetes
\n
<\/b><\/i>Authors<\/b>: Ru Bai, Meng Yu, Liping Liu, Adrian M. Di Bisceglie
\n
Abstract Number: <\/strong>4301
\n
Presentation Type: <\/strong>Poster
\n
Presentation Date and Time:<\/strong> <\/i>Monday, November 7, 2022, 1:00 PM (EST)<\/i>\n<\/p>\n

\nGreater Biochemical Improvements With HTD1801 in Patients With PSC and Elevated Baseline Alkaline Phosphatase
\n
<\/b><\/i>Authors<\/b>: Lisa Forman, Kris V. Kowdley, Bertus Eksteen, Nadege Gunn, Vinay Sundaram, Charles Landis, Stephen A. Harrison, Cynthia Levy, Alexander Liberman, Adrian Di Bisceglie, Gideon M. Hirschfield
\n
Abstract Number: <\/strong>4711
\n
Presentation Type: <\/strong>Poster
\n
Presentation Date and Time:<\/strong> <\/i>Monday, November 7, 2022, 1:00 PM (EST)<\/i>\n<\/p>\n

\n\u201cWe are very pleased to share these data,\u201d said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide. \u201cBoth abstracts support our business strategy in that they provide further evidence of the promising potential for HTD1801 and the treatment of NASH and PSC. The microbiome data demonstrate another positive mechanism of action attribute for HTD1801 and the ALP data demonstrate effectiveness even in more severe disease.\u201d\n<\/p>\n

\nAbout HighTide Therapeutics<\/b>\n<\/p>\n

\nHighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of innovative multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company\u2019s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), and primary sclerosing cholangitis (PSC). HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program.\n<\/p>\n

\nFor more information, please visit www.hightidetx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJeffrey Dao
\n
ir@hightidetx.com<\/a>
+1-650-580-3872\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md. & SHENZHEN, China–(BUSINESS WIRE)–HighTide Therapeutics, Inc. (\u201cHighTide\u201d), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting\u00ae of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50044","6":"format-standard","7":"category-industry"},"yoast_head":"\nHighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md. & SHENZHEN, China–(BUSINESS WIRE)–HighTide Therapeutics, Inc. (\u201cHighTide\u201d), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting\u00ae of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-25T14:01:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221025005159\/en\/1319480\/21\/HIGHTIDE-EN_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022\",\"datePublished\":\"2022-10-25T14:01:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/\"},\"wordCount\":553,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005159\\\/en\\\/1319480\\\/21\\\/HIGHTIDE-EN_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/\",\"name\":\"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005159\\\/en\\\/1319480\\\/21\\\/HIGHTIDE-EN_logo.jpg\",\"datePublished\":\"2022-10-25T14:01:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005159\\\/en\\\/1319480\\\/21\\\/HIGHTIDE-EN_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005159\\\/en\\\/1319480\\\/21\\\/HIGHTIDE-EN_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/","og_locale":"en_US","og_type":"article","og_title":"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022 - Pharma Trend","og_description":"ROCKVILLE, Md. & SHENZHEN, China–(BUSINESS WIRE)–HighTide Therapeutics, Inc. (\u201cHighTide\u201d), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting\u00ae of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-25T14:01:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221025005159\/en\/1319480\/21\/HIGHTIDE-EN_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022","datePublished":"2022-10-25T14:01:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/"},"wordCount":553,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221025005159\/en\/1319480\/21\/HIGHTIDE-EN_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/","url":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/","name":"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221025005159\/en\/1319480\/21\/HIGHTIDE-EN_logo.jpg","datePublished":"2022-10-25T14:01:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221025005159\/en\/1319480\/21\/HIGHTIDE-EN_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221025005159\/en\/1319480\/21\/HIGHTIDE-EN_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/hightide-therapeutics-announces-presentations-at-the-liver-meeting-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50044"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50044\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}